See the DrugPatentWatch profile for Plerixafor
What is plerixafor, and what is it used for?
Plerixafor (also written as AMD3100) is a medicine that blocks the CXCR4 receptor. By interfering with the CXCR4–SDF-1 signaling pathway, it helps move certain blood-forming cells (hematopoietic stem/progenitor cells) from the bone marrow into the bloodstream. This is used to support stem cell collection for transplantation in patients whose own cells are being collected (autologous use). [1]
How is plerixafor given, and what happens around the time of a transplant?
Plerixafor is used as part of a stem cell mobilization strategy. It is typically given shortly before the planned stem cell collection procedure so that more target cells are present in peripheral blood for harvesting. The exact timing and schedule depend on the mobilization plan used at the transplant center. [1]
Who might need plerixafor (and who might not)?
Clinicians consider plerixafor when stem cell mobilization with standard approaches is inadequate or when there is a higher risk that mobilization will fail. Its role is tied to improving the collection of stem cells for autologous transplantation. [1]
What are common side effects people ask about?
Common adverse effects reported with plerixafor include gastrointestinal symptoms (such as nausea and diarrhea) and reactions related to the injection or mobilization process. Patients should discuss their specific risk factors and monitoring plans with their transplant team. [1]
How does plerixafor differ from other mobilization drugs?
Plerixafor is a CXCR4 antagonist. Other commonly used mobilization approaches (such as G-CSF-based regimens) work through different mechanisms to increase stem cell release from the bone marrow. Because plerixafor targets CXCR4 directly, it can be added to or used with these strategies to increase mobilized cell yields. [1]
Is plerixafor approved for children or only adults?
The approved use depends on the specific regulatory label in a given country, including age limits and transplant indications. For up-to-date, label-specific details (including pediatrics), you would need to check the official prescribing information for your region. [1]
Sources
- https://www.ncbi.nlm.nih.gov/books/NBK538173/